Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective

Purpose Deferiprone (DFP), deferasirox (DFX) and deferoxamine (DFO) are used in thalassaemia major (TM) patients to treat chronic iron overload. We evaluated the cost-effectiveness of DFP, compared with DFX and DFO monotherapy, from an Italian healthcare system perspective. Methods A Markov model wa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical drug investigation 2017-05, Vol.37 (5), p.453-464
Hauptverfasser:	Pepe, Alessia, Rossi, Giuseppe, Bentley, Anthony, Putti, Maria Caterina, Frizziero, Ludovica, D’Ascola, Domenico Giuseppe, Cuccia, Liana, Spasiano, Anna, Filosa, Aldo, Caruso, Vincenzo, Hanif, Aishah, Meloni, Antonella
Format:	Artikel
Sprache:	eng
Schlagworte:	Benzoates - administration & dosage Benzoates - economics beta-Thalassemia - drug therapy beta-Thalassemia - economics beta-Thalassemia - epidemiology Blood diseases Cardiovascular diseases Chelation Chelation therapy Cohort Studies Cost analysis Cost control Cost-Benefit Analysis - methods Deferoxamine - administration & dosage Deferoxamine - economics Disease Drug Administration Routes Economic models Eurozone Health care Health Care Costs Heart Hemoglobin Humans Immigration Internal Medicine Iron Iron Chelating Agents - administration & dosage Iron Chelating Agents - economics Italy - epidemiology Medicine Medicine & Public Health Mortality NMR Nuclear magnetic resonance Original Research Article Patients Pharmacoeconomics Pharmacology/Toxicology Pharmacotherapy Pyridones - administration & dosage Pyridones - economics Quality of life Studies Treatment Outcome Triazoles - administration & dosage Triazoles - economics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!